The Contingency Came Off and the Cascade Lost Its Funding: Centrus Gapped Up 8% and Closed Down 5%

Results vs. Consensus

Centrus reported after the close on August 5 and held its call the following morning, August 6, at 8:30 a.m. ET. This is our fourth consecutive note on the company. We initiated at Hold in November at a $277.78 reaction close, upgraded to Outperform in February at $210.16, maintained in May at $231.32, and write this at $178.03. Over the same period the company has gone from an unfunded plan with a $1B equity shelf to a signed $900M public contract, three build partners, two named HALEU offtakers, a $4.5B backlog and no financing contingency on $3B of it.

The quarter itself beat on both lines and the beat is narrow in origin. Uranium revenue of $53.4M, against nothing in the prior-year quarter, is the entire variance and more. SWU revenue, the recurring part of the business, fell 20%. The market read the release correctly and sold it, and the item it sold on sits at the end of the release's backlog paragraph.

Year-over-Year Comparison

Six-Month Comparison

Segment Performance

LEU segment

Segment revenue of $153.4M rose 22%, entirely on $53.4M of uranium sales. SWU revenue fell $25.7M on a 23% volume decline offset by a 3% increase in the average price of SWU sold. Cost of sales rose 36% to $101.8M on uranium volume, with SWU costs down on volume and partly offset by a 13% increase in the average unit cost of SWU sold. Segment gross profit rose $0.9M to $51.6M, on a segment gross margin of 33.6% against 40.3%.

Assessment: Last quarter we recorded a 52% increase in the average realized SWU price and called it first evidence that the contract book was repricing, explicitly graded as one quarter of data on a thin volume base. This quarter the increase is 3%. The honest conclusion is that the Q1 figure was a mix artefact of a 47% volume decline rather than the start of a trend, and the new bull pillar we opened in May does not survive its first test. We retire it as a standing pillar and fold the observation back into the general point that realized pricing follows contract vintage on a schedule the company will not disclose.

The uranium sale deserves the same scepticism it got in November, when a $34.1M sale supplied that quarter's entire revenue increase. Across four quarters uranium revenue has printed $34.1M, $13.4M, $3.0M and $53.4M, which is a pattern only in the sense that it has no pattern. Management confirmed in May that these are opportunistic and cannot be guided. A revenue beat built on one is not a run-rate.

Technical Solutions segment, and the funding withdrawal

Revenue fell 21% to $22.7M on a $5.9M decline from the HALEU Operation Contract, cost of sales fell only 5% to $24.4M, and the segment recorded a gross loss of $1.7M against a $3.2M profit. Operationally the segment did the opposite of what its financials show: the company completed all HALEU production requirements under the demonstration contract two weeks ahead of schedule and has now contractually produced nearly 2 metric tons of HALEU UF6.

The material disclosure is in the backlog paragraph of the release rather than in the bullets or the prepared remarks. The proposed DOE budget for fiscal 2027 contains no further funding for operating the HALEU cascade under the HALEU Operation Contract, which the company states represents approximately $0.8B of the Technical Solutions backlog. Separately, DOE has communicated that it does not currently intend to exercise further options under that contract.

Management's framing on the call was forward-looking rather than defensive.

"While the first new capacity from this transition is expected to come online by 2029, in the interim, we're looking -- we're working with the DOE on agreements to enable the company to privately operate the existing 16-centrifuge HALEU cascade on a commercial basis." — Amir Vexler, President and Chief Executive Officer

Assessment: This is the most consequential negative in four quarters of coverage and it was disclosed in the least prominent place available. The Technical Solutions segment generated $102.5M of FY2025 revenue, roughly 23% of the company, on a cost-plus contract with the government. The proposed budget removes its funding and the customer has said it does not intend to exercise options. Approximately $0.8B of a $4.5B backlog, or roughly 18%, is affected.

Management's answer, converting the cascade to private commercial operation, is strategically the right response and is not yet an agreement. It also carries a real upside if it lands: the same equipment moves from a cost-plus contract earning no fee on part of its scope to commercial HALEU sales into a market where the company has just signed two offtakers. That is a better business. It is also unfunded, unsigned and undated, and it converts a contracted revenue stream into a commercial one at exactly the moment the segment turned loss-making.

Backlog, and the contingency that came off

"With the past quarter funds as well as cash generated from our existing broker business and strong cash balance, we have now met the financing contingency for our more than $3 billion of customer contracts for the purchase of LEU and HALEU. Another key milestone in derisking and advancing our ongoing multibillion-dollar expansion." — Amir Vexler, President and Chief Executive Officer

Assessment: Read the two backlog changes together and the quarter's real content becomes visible. The commercial book grew $600M and, more importantly, stopped depending on the company's ability to raise capital: for four quarters the release said contingent commitments "depend on our ability to secure substantial public and private investment," and this release says they "tend to relate to achievement of operational milestones." That is the condition our initiating note named as the reason not to capitalize the backlog, and it has been satisfied. Meanwhile the government book, which was the funded and non-contingent part, is the piece that just became doubtful. The composition of $4.5B is materially better than the composition of $3.9B was, and the segment that pays today's bills is worse.

One caution on the growth. Of $3.0B of contingent commitments, $2.4B is under definitive agreement, so the incremental $0.6B is not yet definitive. Management confirmed the increase is entirely commercial and excludes the DOE award, and declined to say whether letters of intent are counted.

Key Topics & Management Commentary

Overall Management Tone: Confident, commercially specific, and conspicuously silent on the quarter's largest negative. The call delivered two named HALEU customers, a signed $900M contract, a supplier-lock-in figure, a first-centrifuge date and an Investor Day announcement. The HALEU Operation Contract's defunding was addressed only obliquely, as a transition to private commercial operation, and the one analyst who alluded to it received an answer about revenue guidance instead.

1. Two named HALEU offtakers, with prepayments

The funding avenue described in three consecutive calls without a counterparty produced two in one quarter.

"Another meaningful achievement for Centrus this quarter was the signing of a letter of intent with Oklo for Centrus to supply HALEU to power up to 5 Aurora powerhouses for multiple years starting in 2029... And more recently, we announced an offtake contract for HALEU with X-energy. This marks an important step towards ensuring reliable HALEU supply for next-generation reactors and validates our first-mover advantage in the HALEU market." — Amir Vexler, President and Chief Executive Officer

He was explicit about the financing structure: "Our HALEU offtake commitments generally include prepayment to Centrus, which will be further negotiated in a future definitive agreement. These prepayments are another source of nondilutive, non-debt funding for our expansion and is a structure we intend to utilize in future HALEU offtake contracts."

Assessment: The single best development of the quarter and the answer to a question we have asked since initiation. Customer prepayment is the most shareholder-friendly capital available to this company: it is neither dilution nor leverage, it converts a commercial conversation directly into construction funding, and it aligns the customer with the schedule. Two counterparties in one quarter, one at letter-of-intent stage and one definitive, after three calls of describing conversations, is a genuine step change in the funding path. The qualifications are that the prepayment terms are still to be negotiated in future definitive agreements and that neither contract's size has been disclosed.

2. The financing contingency is gone

The condition attached to more than $3B of customer contracts, present in every prior release we have covered, has been satisfied.

"Importantly, all financial contingencies in our contingent LEU enrichment backlog have now been removed. We continue to feel confident in our existing cash balance, and we believe we are sufficiently funded to meet our near-term capital requirements." — Todd Tinelli, Chief Financial Officer

Management linked it directly to commercial standing.

"The fact that we now have essentially no required contingency there that we have met across the threshold, that makes us a much lower risk start-up and a much lower risk enricher on the market. And I would expect that, that would give us a lot more play with utility." — Amir Vexler, President and Chief Executive Officer

Assessment: At initiation we wrote that $2.3B of contingent backlog "cannot be discounted like contracted revenue and should not be capitalized in a model," because it depended on funding that did not exist. That objection is now answered. What remains conditional is operational: the plant has to be built and milestones met. That is a materially different and more ordinary risk, and it is the reason the composition of this backlog is better than any prior quarter's. The commercial consequence management describes, that a lower-risk supplier gets more engagement from utilities, is plausible and unproven.

3. DOE's proposed budget omits the cascade, and the call barely touched it

The release states that the proposed FY2027 DOE budget contains no further funding to operate the HALEU cascade and that DOE does not currently intend to exercise further options, affecting roughly $0.8B of Technical Solutions backlog. One analyst referred to "the potential roll-off of funding for the operations contract" in a question about revenue guidance, and the answer did not address it.

"We're not providing quarter-over-quarter guidance. However, we're maintaining our guidance for the year. We feel that along with our strong order book and the market maturing that we are able to maintain our guidance at the current sense for revenue and also CapEx." — Todd Tinelli, Chief Financial Officer

Assessment: A segment that produced $102.5M of revenue last year has had its funding proposal zeroed and its option exercises disclaimed by its only customer, and the fullest treatment it received on the call was a plan to negotiate private operation of the same equipment. Fourteen analysts asked questions, and the one who raised it did not press it. That is a coverage failure rather than a company one, since the disclosure itself is clear and complete. For a shareholder the consequences are concrete: the 2027 revenue base is smaller than the 2026 base implies, the Technical Solutions backlog should be discounted heavily, and the reaffirmed 2026 guide is not insulated: DOE's fiscal 2027 begins October 1, 2026, so the fourth quarter is exposed, and management did not say what the guide assumes for the cascade.

4. Supplier contracts at 75%, deliberately over-committed

Critical-supplier contracting moved from roughly a third to roughly 75%, and management explained the commercial posture behind it.

"Our strategy includes risk-reducing measures like locking in a majority of the suppliers deemed critical with larger commitments to help insulate the project from potential price fluctuations." — Amir Vexler, President and Chief Executive Officer

He connected the order book to the buying leverage: "The fact that we're able to lock in larger order books, the fact that we now have more clarity into customer base about the ordering allows us to make more leverage buys and realize savings on the supply side of our build."

Assessment: Taking larger supply commitments than immediately needed, in order to fix price and secure capacity, is the correct move for a first-of-a-kind project in an inflating supply chain, and it is the mechanism by which the customer order book converts into procurement leverage. It also front-loads cash and creates obligations that are hard to unwind if the schedule slips, which is why the acceleration of capital spend and the acceleration of contracting are the same event. Against a 2026 guide of $350M to $500M with $127.4M spent in the first half, the back half carries the majority of it.

5. The first centrifuge, in 2026

The most tangible milestone the company has ever guided to arrives this year.

"The first centrifuge is going to be completed in our Oak Ridge facility sometime in 2026 as we announced... this is probably one of the most exciting steps towards realization and commencement of enrichment in Piketon." — Amir Vexler, President and Chief Executive Officer

Management framed it as proof the supply chain has come together rather than as a production event.

Assessment: One centrifuge is worth nothing in revenue and a great deal in evidence. The build-out's central execution question is whether an American supply chain can manufacture this machine at all, and a completed first article answers it in kind if not in rate. It is also a dated, checkable milestone that does not depend on a government decision. Grade it at year-end.

6. Commercial production in 2029, with "late" removed

Asked to confirm the schedule, the CEO made a small and deliberate correction.

"I would remove the adjective late and just say in 2029, that is our goal, absolutely. Are we -- to use your words, to put a bow on it, we are exploring opportunities and working hard to ensure that we can potentially compress timelines, but there is nothing to announce and no commitments at this point." — Amir Vexler, President and Chief Executive Officer

Assessment: A chief executive volunteering that the schedule is earlier than the analyst assumed, while explicitly refusing to commit to compression, is the right balance. The date was first given in February and is restated now without slipping, which is itself information: first-of-a-kind industrial schedules usually move, and this one has not yet. It remains two and a half to three and a half years from the reporting date, with the Russian supply prohibition arriving a year before it.

7. The SWU reprice did not repeat

The sharpest numerical question of the call asked why costs rose against a small price increase.

"SWU prices have been escalating and have -- are still escalating due to the simple fact that you have demand that is outstripping supply. And more importantly, this is 2026, we still have 2, 3 more years or so until there is capacity that's going to start to come online from numerous projects that have been announced." — Amir Vexler, President and Chief Executive Officer

The CFO's answer on cost was less specific: "the costs relate to a mix of our SWU and uranium costs... the inventory cost is a contractual mix and how we account for the inventory on the books. But again, we're seeing strong SWU prices. Our margins are coming in line with our expectations..."

Assessment: The market commentary is unchanged and credible; the realized number is not what May's was. A 3% increase in the average price of SWU sold, following 52%, against a 13% increase in average unit cost, is the clearest possible demonstration that quarterly realized pricing in this business is a mix outcome rather than a market read. We opened a bull pillar in May on one quarter of data and we retire it here. Management's own repeated instruction, to judge this on a trailing-twelve-month basis, applies symmetrically and we did not apply it symmetrically last quarter.

8. Stock compensation rose to $17.7M on non-employee tax withholdings

SG&A rose $12.8M year over year, and the release attributes it to a $17.2M increase in stock-compensation expense related to non-employee tax withholdings of restricted stock units. The non-GAAP reconciliation excludes $17.7M of stock-based compensation in the quarter against $4.2M a year ago, and $18.1M for the six months against $4.7M.

Assessment: This is the least examined item in the release and it deserves attention. A stock-compensation charge four times the prior-year level, arising from tax withholdings on non-employee awards, is unusual in origin and material in size: it is larger than the entire quarter's GAAP operating income. The cash-flow statement shows equity-related compensation of $18.1M for the six months against $4.7M, so it is a real charge rather than a reclassification, and $0.8M of equity-based compensation was reclassified from equity to liability. It is excluded from adjusted earnings alongside Growth Costs, which is a defensible treatment for a one-time withholding event and a poor one if it recurs. Neither document says which it is.

9. Utilities are described as waiting, and expected to move

Asked about the pace of long-term LEU contracting, the CEO gave the most detailed account of buyer psychology in four calls.

"The buying patterns of the utilities are very different from utility to utility... Some of them have different tolerance for risk or interest in incumbent versus new entrants. And as I said, the fact that we are now delivering centrifuge or we're going to be demonstrating that we're delivering, installing and we also have no financial contingencies. I believe that there is going to be a lot more interest from utilities that are in a wait-and-see mode, and there's quite a few of them there." — Amir Vexler, President and Chief Executive Officer

The CFO added the timing constraint: "obviously, the market anticipated the Russian ban and a lot of the market in the near term, utilities have secured their position. So discussions with the utilities and the RFPs are for the future periods and future periods when we plan to have capacity online."

Assessment: The CFO's addition is the more useful and the less comfortable. Utilities have already covered their near-term needs ahead of the Russian prohibition, so the requests for proposal Centrus is competing for are for periods when its capacity exists, meaning 2029 and beyond. That confirms two things a shareholder should hold: there is no near-term contracting catalyst from utilities, and the broker business remains the only bridge. It also explains why the company's newly disclosed broker-dealer backlog of roughly $0.7B has not grown.

10. Backlog growth is commercial, and excludes the DOE

Asked what drove the $600M backlog increase, the CEO drew a clear boundary and then stopped.

"So unfortunately, I won't be able to get into a lot of details, but I will tell you this does not include the DOE. These are all commercial agreements. The increase in backlog has to do with commercial agreements. I cannot really go into any more detail than that." — Amir Vexler, President and Chief Executive Officer

The analyst had also asked whether backlog includes letters of intent. That part went unanswered.

Assessment: Confirming the growth is commercial rather than the DOE award being counted twice is the important clarification and management gave it directly. The unanswered half matters: the company signed an Oklo letter of intent in the quarter and announced an X-energy definitive contract on the morning of the call, the contingent book grew $600M, and only $2.4B of $3.0B is under definitive agreement. The arithmetic is consistent with the letter of intent being included in backlog and not in the definitive figure, which would be a defensible policy stated nowhere.

11. The at-the-market program was used, sparingly

After a quarter of using none, the company drew a small amount.

"We finished the second quarter with $1.9 billion in unrestricted cash using our ATM opportunistically to acquire proceeds of only $53.9 million." — Todd Tinelli, Chief Financial Officer

Assessment: In February we said we would downgrade if equity issuance resumed materially below $210. Issuance resumed and it was not material: $53.9M is roughly 1.5% of the equity at the reaction close and about 14% of the November draw, in a quarter when the company also removed the financing contingency from more than $3B of contracts. The word "only," volunteered by the CFO, indicates management understands what the market is watching. We treat the trigger as touched and not breached, and we say so rather than quietly dropping it.

12. Two items for the file: index inclusion and supply-chain M&A

Centrus was invited to join the S&P SmallCap 600 in July. Separately, management disclosed that it continues to evaluate acquisitions in its own supply chain, and announced a first Investor Day in December at the Piketon plant.

Assessment: Index inclusion is a liquidity and shareholder-base event rather than a fundamental one, and for a name whose float has turned over repeatedly it is mildly helpful. Supply-chain acquisitions are the item to watch: a company that has not disclosed its own project cost, is guiding to $350M to $500M of annual capital deployment, and is buying long-lead supply at scale, is also considering buying suppliers. That could be excellent capital allocation or a distraction, and there is no framework disclosed for judging which. The December Investor Day at the plant is the most likely venue for the capital-cost disclosure we have asked for in four consecutive notes.

Guidance & Outlook

Implied second-half shape: the reaffirmed guide of $450M to $500M against $252.8M delivered in the first half leaves $197.2M to $247.2M for the second half, or roughly $98.6M to $123.6M a quarter. That is a step down from the first half's $126.4M quarterly average and from the second quarter's $176.1M. The guide therefore embeds a materially slower back half, which is consistent with a first half that carried $56.4M of opportunistic uranium sales. A shareholder should not read the reaffirmation as conservatism.

On capital: $127.4M of capital spend in the first half against a $350M to $500M annual guide implies $222.6M to $372.6M across the second half, or roughly $111M to $186M a quarter, against $82.2M in the second quarter. Management has said for two consecutive quarters that the pace will accelerate. Against $1,868.5M of cash and a signed $900M milestone-paid contract, the programme remains funded.

Street at: pre-print consensus was $146.33M to $148.8M of revenue and $0.92 to $0.97 of adjusted EPS, both beaten heavily. Full-year revenue consensus stood near $458.7M against a reaffirmed guide midpoint of $475M, so the company's own midpoint sits slightly above the Street's number. The guide does not explain why an 18% to 20% revenue beat could not hold a 7.7% opening gap.

Analyst Q&A Highlights

The X-energy agreement and delivery cadence

The first question sought the commercial detail behind the morning's announcement.

Q: "Just really quickly on the X-energy partnership. Could you just give us a sense of the cadence of any deliveries you expect to make? I know X-energy is planning to bring their first facility on kind of in the first half of '28. And then do you expect any of those volumes to come from the demonstration cascade that you're converting to commercial offtake?"
— David Choe, on for Jon Windham, UBS

A: "I would like to remind you that the other exciting thing here is that these HALEU agreements include a prepayment as well, which is significantly helpful to us. Now to your specific question, unfortunately, I cannot provide too many details around deliveries and other specific terms under the contract... But as I said, all in all, just as a general statement, it's exciting. It's definitive, which is very important, and we're looking forward to filling it."
— Amir Vexler, President and Chief Executive Officer

Assessment: The word doing the work is "definitive." An offtake contract that is legally binding, rather than a memorandum, is what the funding path has lacked since our initiation, and management chose to emphasize the prepayment attached to it. The question about whether volumes come from the converted demonstration cascade went unanswered, which is the same question the FY2027 budget withdrawal makes urgent.

Buyer behaviour ahead of the 2028 import ban

The 2028 prohibition returned to the call after going unmentioned in May.

Q: "Given that we're less than 18 months from the Russian import ban going into effect, have you seen any changes in buyer behavior? How should we think about any potential changes in financials, including your inventory or working capital, assuming customers prefer to prebuy... just of any change of customer behavior that you're seeing?"
— William Peterson, JPMorgan

A: "You may have heard me say this before that we do see sort of tightness on the supply side towards the end of the decade. I do believe we're starting to see some of that. We're seeing strong momentum as far as customer interest generally in buying SWUs and turning specifically to Centrus for that as the newcomer and the new entrant into the market... we're seeing that momentum play in favor of the sellers."
— Amir Vexler, President and Chief Executive Officer

Assessment: The question about inventory and working capital was the better half and went unanswered, which is a pity because the balance sheet shows what a prebuy looks like: inventories rose to $377.1M from $322.9M and inventories owed to customers and suppliers rose to $235.7M from $192.7M. The qualitative answer is unchanged from three prior calls. Eighteen months from a statutory supply cut, the company's own capacity is still three years out.

Where further cost savings come from

An analyst asked whether the $300M identified in the prior quarter can be extended.

Q: "On the cost savings front, obviously, the partnership with Palantir is already proving to be extremely valuable. But can you just give us an idea of what the picture for further cost savings might look like throughout the life of your expansion project just in terms of comparable magnitude to what you've been able to achieve thus far..."
— Luke, on for Eric Stine, Craig-Hallum

A: "The fact that we're able to lock in larger order books, the fact that we now have more clarity into customer base about the ordering allows us to make more leverage buys and realize savings on the supply side of our build... In terms of being able to give you details as to what it is numerically and what we're targeting, that's not something that we've talked about on this phone call..."
— Amir Vexler, President and Chief Executive Officer

Assessment: No updated savings figure, and no portion of the previously identified $300M described as realized. That is a direct failure of one of the five items we set out to grade this quarter. The mechanism described, converting order-book clarity into procurement leverage, is credible and consistent with the 75% supplier contracting. What a shareholder cannot do is verify any of it, because there is still no disclosed project cost for savings to be measured against.

Comparing the two HALEU contracts

An analyst asked for a structural comparison rather than terms, which is the right way to ask.

Q: "If you look at the 2 HALEU contracts you recently signed with Oklo and X-energy today, can you highlight anything where they may be the same or differ maybe in size, timing, milestone structure? Is one further along, more definitive? Do you either have take-or-pay commitments?"
— Mark Shooter, William Blair

A: "The LOI is a step that precedes a definitive contract. This is an agreement over general terms as we see them. And once we get to that point, we're very close to finalizing contractual terms and conditions... The third similarity that we're seeing is prepayments. We're seeing the willingness, the ability and our sort of strong preference for a prepayment, which adds significantly to the nondilutive capital that we're able to invest."
— Amir Vexler, President and Chief Executive Officer

Assessment: The most useful answer of the call for anyone tracking the funding path. Prepayment is described not as a feature of one deal but as a structure the company prefers and intends to repeat, and management characterises a letter of intent as being close to definitive terms rather than an expression of interest. The take-or-pay question went unanswered, which matters: without it, a prepaid HALEU commitment for 2029 delivery is capital with an unquantified return obligation attached.

Guidance, and the funding roll-off

The one question that touched the quarter's biggest negative asked where it sits in the guide.

Q: "I just wanted to come back to the guidance. And could you just maybe remind us what's driving the bookings there? The release had mentioned the potential roll-off of funding for the operations contract. So just wanted to understand where that may sit within the revenue guidance range."
— Ted Giletti, on for Vikram Bagri, Citigroup

A: "We're not providing quarter-over-quarter guidance. However, we're maintaining our guidance for the year. We feel that along with our strong order book and the market maturing that we are able to maintain our guidance at the current sense for revenue and also CapEx. But additionally, another strong item is that we've increased our headcount around the Piketon facility..."
— Todd Tinelli, Chief Financial Officer

Assessment: The question named the funding roll-off and the answer did not address it. Management did not say what the reaffirmed guide assumes for the cascade once DOE's fiscal 2027 begins on October 1, 2026, and no follow-up came. This exchange is the whole reason a reader should go to the release's backlog paragraph rather than relying on the call. It is also why the reaffirmed 2026 guide tells a shareholder nothing about 2027.

How much capacity should be under offtake

An analyst asked for the target contracted share of future capacity.

Q: "Just sort of big picture, what's your thinking on the amount of your future capacity that you hope to have in terms of offtake agreements signed up? This, I guess, is a HALEU specific question. But how much of capacity do you hope to have offtake agreements signed for?"
— Robert Brown, Lake Street Capital Markets

A: "At this point, based on what we're locking in, we're not really changing the proportions of what we're building out. We are going to be building both. We have the flexibility to build both. Depending on the customers that step forward and are making firm commitments, that's what we're going to be building. And obviously, we're going to be looking for solid commitments for as long of a term contract as possible."
— Amir Vexler, President and Chief Executive Officer

Assessment: No target share, which is consistent with a demand-led build and unhelpful for modelling. The one substantive statement is that the LEU and HALEU proportions are unchanged despite two HALEU contracts landing in the quarter, which suggests the HALEU wins are within the 12-metric-ton plan rather than expanding it. Anyone expecting the offtake announcements to trigger a capacity increase should note that management explicitly said they have not.

Lead-time compression

An analyst returned to the schedule, asking about time rather than cost.

Q: "Maybe a follow-up on your work with Palantir and efficiencies more broadly. You discussed efforts in one of the previous responses on the cost side. But could you give more detail on progress you're looking to make on lead time reduction?"
— Ryan Pfingst, B. Riley Securities

A: "We're backing into commercial agreements. And quite frankly, the commercial agreements are demanding even faster timelines. There is a gap in the market in terms of supply... So there is really a tangible and real reward to where we can come to market with enrichment capacity as soon as possible... lead times really translate into enhanced revenue and being able to realize revenue much earlier, much sooner."
— Amir Vexler, President and Chief Executive Officer

Assessment: The disclosure buried in this answer is that customers are asking for delivery sooner than the current schedule supports. That is a demand signal and a risk statement at once: it confirms the market wants capacity before 2029 and it means the contracts being signed have timing expectations the plant must meet. No compression has been committed to, and management said so directly in a later answer.

Capital cadence into 2027

An analyst asked for the shape of spending beyond this year.

Q: "Just as we think about the CapEx ramp through the back half of the year and the completion of the centrifuge. How should we think about kind of the cadence of the balance of the spend through the end of the year? And then as we kind of think about into 2027, where that CapEx number kind of filters out?"
— Nicholas Amicucci, Evercore

A: "This project will continue to ramp up. We're not going to provide guidance just at this point for -- beyond 2026... What we believe is that accelerated spend and moving forward with our project in addition to increased customer demand and backlog allow us to move at a cadence that will meet our customer demands for their deliveries in the future period."
— Todd Tinelli, Chief Financial Officer

Assessment: A refusal to guide 2027 capital in the quarter the company signed two offtake contracts and a $900M government award. The February call said spending after 2026 gets "more linear" once the first year's long-lead procurement and prepayments pass; nothing here contradicts that, and nothing quantifies it. With $1,868.5M of cash, a milestone-paid $900M contract and prepayments in prospect, the funding question is less pressing than it was, and the December Investor Day is the obvious venue for the answer.

Hiring and schedule risk

An analyst asked whether faster hiring means a faster plant.

Q: "On the hiring front, you guys continue to make obviously positive progress on accelerating the hiring goals at Piketon. Can you touch on like the potential, I guess, derisking or accelerating of timelines to first cascade given the hiring acceleration? Are those correlated at all?"
— Jeffrey Grampp, Northland Capital Markets

A: "Being able to improve lead times is tangible real benefit to the company in terms of our ability to get on the market quicker. So a lot of our efforts are associated with going faster and taking cost out. Some of the acceleration in adding the workforce that you referenced and as we've talked about in our guidance is directly related to that... but obviously, nothing new to announce at this point."
— Amir Vexler, President and Chief Executive Officer

Assessment: The CFO's addition explained the dependency chain better than the CEO's answer: Oak Ridge manufactures the centrifuges, they ship to Piketon, and Piketon must be ready to receive and install them. A Piketon hiring target raised twice in two quarters, to at least 175 from at least 50 in February, is therefore an installation-readiness signal rather than a manufacturing one. It is the most concrete evidence available that the 2029 date is being worked toward rather than merely repeated.

SWU price and cost dynamics

The most numerically pointed question of the call asked why costs rose alongside a small price gain.

Q: "Could you talk about the SWU price dynamics here? I think if I heard right, the prices went up 3% during the quarter, whereas the costs went up 30%. What are the drivers for the costs growing up?"
— Sameer Joshi, H.C. Wainwright

A: "Well, the costs relate to a mix of our SWU and uranium costs. Obviously, each -- we can't comment on specific cost of each deal, but the inventory cost is a contractual mix and how we account for the inventory on the books. But again, we're seeing strong SWU prices. Our margins are coming in line with our expectations, and we continue to see market demand that will maintain those SWU prices."
— Todd Tinelli, Chief Financial Officer

Assessment: The analyst's 30% figure does not appear in the release, which discloses a 13% increase in the average unit cost of SWU sold and a 36% increase in LEU segment cost of sales driven by uranium volume rather than SWU. Management did not correct it, which is a small failure of precision on the number that most determines the segment's economics. The substantive answer, that cost is a contractual and inventory-accounting mix, is the same non-answer given in each of the prior three calls.

Utility contracting timing

The most forward-looking question asked when incremental LEU orders arrive.

Q: "Maybe you can give us an update just on how discussions are going with utilities for LEU on potential long-term contracts now that we've met financial contingencies. How should we think about the cadence for incremental orders between now and 2029?"
— Christopher Souther, Truist

A: "The fact that we now have essentially no required contingency there that we have met across the threshold, that makes us a much lower risk start-up and a much lower risk enricher on the market... I will add, and I said this before as well, that some of these discussions don't result in the linear sort of numbers that you can track quarter-to-quarter. They're lumpy and how they're being delivered."
— Amir Vexler, President and Chief Executive Officer

Assessment: The commercial logic that removing the financing contingency lowers perceived counterparty risk is sound and is the clearest statement of why this quarter's balance-sheet event should convert into orders. The CFO's follow-on set the expectation properly: utilities have covered near-term needs ahead of the Russian ban, so the requests for proposal are for periods when Centrus expects to have capacity. Incremental LEU contracting is therefore a 2029-and-beyond book, and no near-term catalyst should be modelled from it.

Earnings power of the combined business

The final question asked the one thing four calls have never addressed.

Q: "As you transition the HALEU cascade from cost reimbursable DOE work to commercial operations, what is the fully ramped earnings power of the combined LEU and HALEU business look like? And if you could say a couple of things about what needs to go right over the next 18 to 24 months to get there, that would be great."
— Peyton, on for Joseph Osha, Guggenheim Securities

A: "We don't provide any additional guidance on that. Obviously, the transition of the demo cascades to the commercial is demonstrating our ability to operate these cascades, our ability to produce HALEU that's out in the market... Obviously, these require LEU feedstock. This will develop over time. But currently, we can't provide any additional guidance on this."
— Todd Tinelli, Chief Financial Officer

Assessment: The right question, asked last, and declined. Four quarters into coverage there is still no disclosed capital cost, no target unit cost, no hurdle price and no earnings-power framework for the asset that constitutes most of the equity value. The CEO's addition was the useful part: the demonstration cascade transitioning to commercial operation is evidence the technology works well enough to sell from. The December Investor Day is the last venue before this becomes a pattern rather than a gap.

What They're NOT Saying

1. What the loss of DOE cascade funding does to 2027. The release quantifies the affected backlog at approximately $0.8B and neither document quantifies the revenue effect, in a segment that produced $102.5M in FY2025. The guidance reaffirmation covers calendar 2026 only, and neither document says what it assumes for the fourth quarter, which falls in DOE's fiscal 2027.
2. Any terms of the commercial cascade operation. Management says it is working with DOE on agreements to privately operate the existing 16-centrifuge cascade. No structure, no lease or ownership arrangement, no fee, no date, and no statement of whether HALEU sold to Oklo or X-energy would come from it.
3. The size of either HALEU offtake contract. Two counterparties named, one definitive, and no volume, value, duration, price mechanism or prepayment amount for either. The take-or-pay question was asked and unanswered.
4. Whether letters of intent are in backlog. Asked directly. Not answered. Contingent commitments grew $600M to $3.0B while the definitive portion stayed at $2.4B, which is consistent with a letter of intent being counted, under a policy stated nowhere.
5. The Piketon capital cost. Fourth consecutive quarter. Now alongside a signed $900M award, two offtake contracts, 75% supplier contracting and a $560M disclosed Oak Ridge figure.
6. Any update on the $300M of cost savings. No revised figure and no portion described as realized, one quarter after it was announced as identified and expected to grow.
7. Why stock compensation rose to $17.7M. Attributed to non-employee tax withholdings on restricted stock units and otherwise unexplained. It exceeds the quarter's entire GAAP operating income, and neither document says whether it recurs. No analyst asked.
8. 2027 capital spending. Explicitly declined, in the quarter the company signed the contract and the offtakes that determine it.
9. Inventory and working capital ahead of the 2028 ban. Asked directly. The qualitative half was answered and the balance-sheet half was not, while inventories rose to $377.1M from $322.9M and inventories owed to customers and suppliers rose to $235.7M from $192.7M.
10. Anything further on supply-chain acquisitions. Disclosed in one sentence as an ongoing evaluation, with no criteria, size range or capital allocation framework, by a company that has not disclosed the cost of its own project.
11. The Phase 2 fee. Fourth consecutive quarter. The demonstration contract's production requirements are now complete, and the fee on costs incurred since November 2024 remains unquantified and unresolved, with no analyst asking in four calls.
12. The NNSA opportunity. Fourth consecutive quarter with no value, scope or date. Described this quarter only as continuing to work with NNSA on its intent to sole source.

Market Reaction

• Pre-print setup: LEU closed at $187.63 on August 5, down 22.7% year to date from $242.76 against the S&P 500's +12.8%, and down 12.2% over the trailing twelve months from $213.80. The stock had firmed into the print, up 7.7% over the trailing thirty days from $174.23. The 52-week closing range entering the print was $146.61 to $436.00.
• Reaction session: the stock opened at $202.00 on August 6, 7.7% above the prior close, traded a range of $176.00 to $203.18, and closed at $178.03, down 5.1% or $9.60.
• Intraday pattern: the high of $203.18 marked an 8.3% gain and the low of $176.00 a 6.2% decline. The stock closed 1.2% above its low, at the bottom of a 15.4% intraday range, having given up the entire opening gap in an 11.9% decline from the open.
• Volume: 1.0M shares against a 30-day average of 0.8M, or 1.3x normal, the lightest of the four reaction sessions we have covered.
• Market context: the S&P 500 fell 0.2% on the session, so roughly 4.9 points of the 5.1% decline was idiosyncratic.

This is the most legible reaction session of the four. The stock gapped up 7.7% on a headline beat of 18% to 20% on revenue and 82% to 92% on adjusted EPS, then fell for the rest of the day and closed 1.2% off the low. A full round trip and more, from a $202.00 open to a $178.03 close, is an 11.9% intraday decline. That is not profit-taking. That is a market reading the release and the call and changing its mind.

Two findings explain it, in descending order of importance. First, the DOE's proposed FY2027 budget removes funding for the HALEU cascade and DOE does not intend to exercise further options, affecting roughly $0.8B of backlog in a segment that was 23% of last year's revenue. It sits in the backlog paragraph and the call addressed it only obliquely. Second, the beat is a single opportunistic uranium sale of $53.4M that the company has said cannot be forecast, while SWU revenue fell 20% and the average realized price rose only 3% after 52%. The full-year guide is not part of the explanation: its $475M midpoint sits slightly above a Street near $458.7M.

The light volume is worth noting alongside all of that. At 1.3x average, against 1.6x, 2.5x and 1.6x in the prior three reaction sessions, this was a decline achieved without heavy turnover, which suggests conviction holders neither bought the gap nor sold the fade in size.

Some perspective on the base. At $178.03 the stock is down 26.7% year to date in a market up 12.8% entering the print, and down 45.3% from the $325.73 close before our November initiation. Across four prints the reaction sessions have been (14.7)%, (20.7)%, +12.3% and (5.1)%. Over the same four quarters the company signed a $900M government contract, removed the financing contingency from more than $3B of customer commitments, named two HALEU offtakers with prepayments, contracted 75% of critical suppliers and grew backlog from $3.9B to $4.5B. The share price and the asset have moved in opposite directions for a year.

Street Perspective

Debate: Does removing the financing contingency matter more than losing the cascade funding?

Bull view: The bull case holds that these are not comparable in size or in kind. The financing contingency covered more than $3B of customer contracts and was the single condition that made the backlog uncapitalizable; it is gone, and what remains are operational milestones the company controls. The cascade funding affects a demonstration contract that was always transitional, that has now completed its production requirements early, and whose equipment management intends to convert to commercial HALEU sales into a market where it has just signed two customers.

Bear view: The bear response is that the contingency removal is a statement about a plant that will not produce until 2029, while the cascade funding is revenue and cash from the fourth quarter of 2026, when DOE's fiscal 2027 begins. Technical Solutions was $102.5M of FY2025 revenue, is now loss-making at the gross line, and its customer has said it does not intend to exercise further options. Converting it to commercial operation requires an agreement that does not exist.

Our take: The bulls have the larger number and the bears have the nearer one, and the nearer one is why the stock fell. Removing the financing contingency is genuinely the most important structural event of our coverage, and it changes what the backlog is worth in a model rather than what the company earns next year. Losing the cascade funding removes roughly a fifth of the revenue base at the exact point the build-out consumes the most cash. Both are true, and a shareholder who cannot wait until 2029 should weight the second.

Debate: Was the SWU reprice real or was Q1 a mix artefact?

Bull view: The optimistic reading is that both quarters are mix and the trend is upward regardless. The published long-term price curve has risen year to date while spot holds last year's high, no new Western capacity arrives for two to three years, and management describes a seller's market it expects to persist. Quarterly realized prices on a lumpy delivery schedule were never going to trace the curve, which is precisely why the company asks to be judged on a trailing-twelve-month basis.

Bear view: The skeptical reading is simpler. The realized price rose 52% in a quarter with 47% lower volume and 3% in a quarter with 23% lower volume, and the average unit cost rose 45% and then 13%. Two quarters of data support the conclusion that realized pricing is set by which contracts happen to deliver, and provide no evidence that the curve is reaching revenue at all.

Our take: The bears are right and we were wrong to open a pillar on one quarter. In May we recorded the 52% figure as first evidence of a repricing book while noting the thin volume base; the honest conclusion now is that the base was doing the work. We retire that pillar. What survives is the older and more durable point: the resale business earns contract vintages, the vintages roll on a schedule the company will not disclose, and the market price is a statement about the future plant rather than the present business.

Debate: Are two HALEU offtakers enough to change the funding picture?

Bull view: The bull argument is that this is the third non-dilutive funding source to materialize in nine months, after the $900M procurement and the company's own cash. Prepayment is capital that arrives from customers, carries no interest and no dilution, and is described by management as a structure it intends to repeat in future HALEU contracts. One agreement is definitive. Combined with a signed government contract and $1.87B of cash, the near-term programme no longer depends on equity markets at all.

Bear view: The bear response is that no prepayment has been received, no amount disclosed, and the terms are explicitly still to be negotiated in future definitive agreements. One of the two contracts is a letter of intent. Prepayment is also not free: it is deferred revenue with delivery obligations attached to a plant that will not exist for three years, and the take-or-pay question was asked and not answered.

Our take: The bulls have it, with the amount unknown. What changed this quarter is categorical rather than quantitative: for three calls prepayment was a described avenue with no counterparty, and now there are two named ones and a stated intention to make it standard. That is the difference between a funding plan and a funding source. The obligations the bears identify are real and are the ordinary shape of pre-selling capacity, which is how first-of-a-kind industrial projects have always been financed.

Model Update Needed

Valuation: At the $178.03 reaction close on 19,952,858 shares of Class A and Class B common stock outstanding at June 30, the equity is worth roughly $3.55B. Netting approximately $691M of net cash gives an enterprise value near $2.86B. That is 6.0x trailing-twelve-month revenue of $473.9M, 6.0x the midpoint of the 2026 guide, 25.5x trailing-twelve-month gross profit, 0.64x the $4.5B headline backlog and roughly 1.9x the non-contingent portion. The equity trades at 38.6x trailing-twelve-month adjusted net income of $92.0M. Enterprise value has fallen 26% since our May note and 38% since our November initiation, while the backlog has grown from $3.9B to $4.5B and its financing contingency has been removed.

We maintain Outperform and trim the fair value range to $240 to $300 from $280 to $340. The midpoint of $270 implies +51.7% from the $178.03 reaction close; the $240 low end implies +34.8% and the $300 high end +68.5% against the same close. The trim reflects two specific things: the loss of proposed FY2027 funding for the HALEU cascade, which removes a material part of the near-term revenue base, and the retirement of the repricing pillar we opened in May. The rating is maintained because the offsetting facts are larger in the medium term: the financing contingency is gone, the $900M contract is signed, two HALEU offtakers with prepayments are named, and the enterprise value is now below two thirds of a backlog whose only remaining conditions are operational.

We would note plainly that an implied return above 50% is at the top of what our Outperform band normally carries, and that the reason is a share price that has fallen 45% in nine months rather than a raised valuation. The offsetting risks that keep us from a more aggressive stance are unchanged: no disclosed capital cost after four quarters, a 2029 first cascade, and a statutory Russian import prohibition arriving in 2028, a year earlier.

Thesis Scorecard Post-Earnings

Five items were set out in May to be graded this quarter.

Overall: The most consequential quarter of our coverage in both directions. On the constructive side, the pillar that was failing at initiation is now confirmed: this company's funding no longer depends on selling stock. A signed $900M procurement, prepayment established as a repeatable structure with two named counterparties, a financing contingency removed from more than $3B of customer contracts, and $53.9M of equity issued in six months, together answer the question our Hold rating was built around. On the destructive side, a new bear point opened, the pillar we opened last quarter is retired after one test, and the older reseller critique is restored by a 3% realized price increase.

The pattern across four quarters is unusual and worth naming. The asset has improved in every reporting period and the share price has fallen 45%. That divergence is either the market pricing a 2029 delivery date and three more years of cash consumption correctly, or it is the market losing patience with a story whose value is dated. Our rating says the second, with the acknowledgement that a shareholder must be willing to hold through the 2028 supply cliff to collect.

Action: Maintaining Outperform; trimming fair value to $240 to $300 from $280 to $340. On the February downgrade trigger, equity issuance below $210: issuance resumed at $53.9M, roughly 1.5% of the equity and 14% of the November draw, in the quarter the financing contingency was removed. We treat it as touched and not breached. What we will grade next quarter and at the December Investor Day: whether the Piketon capital cost is finally disclosed, whether an agreement to operate the HALEU cascade commercially is signed, whether the second-half revenue step down materializes as guided, whether the first centrifuge is completed in 2026, and whether either HALEU offtake produces a disclosed prepayment amount. We revert to Hold if the cascade transition fails to produce an agreement by the fourth-quarter print, or if the Investor Day passes without a capital cost.